Embedded Files
According to a comprehensive market analysis by Intel Market Research, the global Close Needleless Infusion Connector market was valued at USD 1,053 million in 2024 and is projected to reach USD 1,581 million by 2032, growing at a steady CAGR of 6.1% during the forecast period (2025–2032). This growth trajectory reflects the expanding adoption of needle-free infusion technologies in healthcare settings, driven by heightened infection control protocols and increasing demand for safer drug delivery systems.
What Are Close Needleless Infusion Connectors?
What Are Close Needleless Infusion Connectors?
Close needleless infusion connectors represent a critical advancement in intravenous therapy systems. These devices serve as sterile interfaces between infusion sets and catheters, maintaining a closed pathway that prevents microbial ingress while eliminating needle-stick risks. Unlike conventional open systems, these connectors utilize mechanical valves or split-septum designs to ensure uninterrupted fluid delivery with zero air exposure – a feature particularly vital for long-term therapies like chemotherapy, parenteral nutrition, and critical care medications.
The technology has gained substantial traction since receiving FDA clearance in 2016 for critical care applications. Modern iterations incorporate antimicrobial coatings and pressure-balancing mechanisms that further reduce catheter-related bloodstream infections (CRBSIs), which according to clinical studies, can be decreased by up to 67% when using closed systems compared to traditional methods.
📥 Download FREE Sample Report:
Close Needleless Infusion Connector Market - View in Detailed Research Report
Key Market Drivers
Key Market Drivers
1. Rising Global Emphasis on Healthcare-Associated Infection (HAI) Prevention
The World Health Organization estimates that 7-10% of hospitalized patients acquire at least one HAI, with bloodstream infections accounting for significant mortality rates. This has propelled regulatory mandates for closed-system adoption across North America and Europe, where reimbursement policies now incentivize hospitals implementing needle-free technologies. The CDC's 2023 guidelines specifically recommend closed connectors for all central line access, creating substantial market pull.
2. Technological Advancements in Connector Design
Manufacturers are focusing on three critical innovation areas:
Multi-access ports: Allowing simultaneous infusion and blood withdrawal without disconnection
Negative/positive pressure mechanisms: Preventing reflux and catheter occlusions
Biofilm-resistant materials: Incorporating silver-ion or chlorhexidine coatings to inhibit microbial colonization
Recent clinical trials demonstrate that next-generation connectors can maintain sterility for up to 96 hours of continuous use – a significant improvement over earlier models requiring daily changes.
Market Segmentation
Market Segmentation
By Product Type
Positive Pressure Connectors
Negative Pressure Connectors
Neutral Pressure Connectors
By Application
Hospitals (ICU, Oncology, General Wards)
Ambulatory Surgical Centers
Home Care Settings
By Region
North America (38% market share)
Europe (29% market share)
Asia-Pacific (Fastest growing at 8.2% CAGR)
Competitive Landscape
Competitive Landscape
The market features a mix of multinational medtech firms and regional specialists, with BD, B. Braun, and ICU Medical collectively holding over 55% market share. Recent developments include:
BD's 2023 launch of the Nexiva™ Closed IV Catheter System with integrated connector
B. Braun's acquisition of a Chinese connector manufacturer to expand Asia-Pacific production
Terumo's FDA-cleared SurFlash® Needleless Connector featuring zero-fluid-displacement technology
📘 Get Full Report Here:
Close Needleless Infusion Connector Market - View in Detailed Research Report
About Intel Market Research
About Intel Market Research
Intel Market Research is a leading provider of strategic intelligence, offering actionable insights in medical devices, pharmaceuticals, and healthcare technologies. Our research capabilities include:
Real-time competitive benchmarking across 42 countries
Clinical trial outcome analysis and technology adoption forecasting
Regulatory pathway mapping for novel medical technologies
🌐 Website: www.intelmarketresearch.com
📞 Americas: +1 (332) 242-2945
🔗 LinkedIn: Follow Our Latest Research
Page updated
Google Sites
Report abuse